Crossover trial of simvastatin versus pravastatin in patients with primary hypercholesterolemia

Journal of Cardiovascular Pharmacology

Volumn 30, Issue 1, 1997, Pages 142-147

  Sasaki, Susumu ^a   Sawada, Shohei ^a   Nakata, Tetsuo ^a   Itoh, Hiroshi ^a   Takeda, Kazuo ^a   Nakagawa, Masao ^a   Kuriyama, Kinya ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Crossover trial; LDL cholesterol; Pravastatin; Simvastatin; Total cholesterol

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DYSURIA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; POLLAKISURIA; PRIORITY JOURNAL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS; CHOLESTEROL; CROSS-OVER STUDIES; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPIDS; LOVASTATIN; MALE; MIDDLE AGED; PRAVASTATIN; SIMVASTATIN;

EID: 0030692775     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199707000-00021     Document Type: Article

References (29)

1. Kannel WB, Castelli WP, Gordon T. Serum cholesterol, lipoproteins and the risk of coronary heart disease: the Framingham study. Ann Intern Med 1971;74:1-12.
2. Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial. JAMA 1986;256:2823-8.
3. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251(3):365-74.
4. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 1976;72:323-6.
5. Biheimer DW, Grundy SW, Brown MS, Goldstein JL. Mevinolin and cholestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 1983;80:4124-8.
6. Tikkanen MJ, Bocanegra TS, Walker F, Cook T. Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol. Am J Med 1989;87:47-53s.
7. Stein E, Kreisberg R, Miller V, Mantell G, Washington L, Shapiro DR. Effects of simvastatin and cholestyramine in familial and hypercholesterolemia. Arch Intern Med 1990;150:341-5.
8. Pietro DA, Alexander S, Mantell G, Staggers JE, Cook TJ. Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II). Am J Cardiol 1989;63:682-6.
9. National Cholesterol Education Program Coordinating Committee (NCEP). summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adults treatment panel II). JAMA 1993;269(23):3015-23.
10. Pan HY. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. Eur J Clin Pharmacol 1991;40(suppl 1):s15-8.
11. Todd PA, Goa KL. Simvastatin, a review of its pharmacological properties and therapeutic potential in hypercholesterolemia. Drugs 1990;40(4):583-607.
12. Germerschausen JI, Hunt VM, Bostedor RG, et al. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun 1989;158(3):667-75.
13. Slatar EE, et al. Mechanism of action and biological profile of HMG CoA reductase inhibitors: a new therapeutic alternative. Drugs 1988;36(suppl 3):72-82.
14. Nagata Y, Hidaka Y, Ishida F, et al. Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells. Biochem Pharmacol 1990;40(4):843-50.
15. Ishida F, Watanabe K, Sato A, et al. Comparative effects of simvastatin (MK-733) and pravastatin (CS-514) on hypercholesterolemia induced by cholesterol feeding in rabbits. Biochim Biophys Acta 1990;1042:365-73.
16. Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol 1993;71:1408-14.
17. Lambrecht LJ, Malini PL. European Study Group: efficacy and tolerability of simvastatin 20 mg vs. pravastatin 20 mg in patients with primary hypercholesterolemia. Acta Cardiol 1993;48:541-54.
18. Douste-Blazy P, Riberio VG, Seed M. European Study Group: comparative study of the efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia Drug Invest 1993;6:353-61.
19. Steinhagen-Thiessen E. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Cardiology 1994;85:244-54.
20. Yamamoto A, Yokoyama S, Yamamura T. Escape phenomenon occurs by lowering cholesterol with a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor in patients with familial hypercholesterolemia. Atherosclerosis 1993;71:257-60.
21. Sviridov DD, Endo A, Pavlov MY, Repin VS. Time response of cholesterol synthesis inhibition by compactin-related compounds: in vitro quantitation of the "escape phenomenon." Lipids 1993; 28:569-71.
22. Naruse M, Yoshimoto T, Naruse K, Tanaka M, Hase M, Demura H. Effects of simvastatin on the escape phenomenon following pravastatin therapy in patients with hypercholesterolemia. J Jpn Atheroscler Soc 1994;22(4):301-6.
23. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994;344:1383-9.
24. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993;72:1031-7.
25. MAAS investigators. Effects of simvastatin on coronary atheroma: the multicentre anti-atheroma study (MAAS). Lancet 1994;344: 633-8.
26. Furberg CD, Byington RP, Crouse JR, Espeland MA. Pravastatin, lipids, and major coronary events. Am J Cardiol 1994; 73:1133-4.
27. Dujovne CA, Chremos AN, Pool JL, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. Am J Med 1991;91 (suppl 1B):25S-30S.
28. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987; 84:7725-9.
29. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332:488-93.